fashion -WSS

fashion

author：entertainment 2025-09-28 23:30:08 - browse：1

Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Readout LOUD podcast: Live from the 2023 STAT Summit

entertainment

WSS

Questions loom on AstraZeneca cancer drug as safety concerns ebb

FDA panel endorses Alnylam’s heart drug — after picking it apart

Long Covid needs a new name — and a new frame

STAT Readout Newsletter: Biotech news today

Telehealth for opioid use disorder is lifesaving

FDA panel endorses Alnylam’s heart drug — after picking it apart

focus

fashion

entertainment

What does generative AI mean for health care? We asked experts

How medical schools plan to diversify without affirmative action

23andMe had bad news about my health. I wish a person had delivered it

Roche drug slashes death risk in early

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

PEPFAR is under serious threat — and so is global health

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

hotspot

Roche drug slashes death risk in early

Generate Biomedicines machine learning biotech raises $273M

White House touts steps to stem shortages of cancer treatments

Readout LOUD podcast: Live from the 2023 STAT Summit

STAT Summit: Ending the crisis of Black deaths in the U.S.

Food makers to regulators: Ultra

entertainment

leisure time

focus

focus